Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11

Peng, Ho-Jen; Su, Song Nan; Chang, Zo-Nan; Chao, Pei-Ling; Kuo, Shi‐Wen; Tsai, L.-C.

doi:10.1016/s0264-410x(02)00029-4

Cited by 45 publications

(56 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results have been demonstrated with DNA vaccines encoding allergens of house dust mite [12,19,20,21,22,23] and a DNA vaccine coding for the major milk allergen bovine β-lactoglobulin [24]. …”

Section: Th1-biased Immunity – the Key To Dna-based Allergy Vaccinationsupporting

confidence: 76%

See 1 more Smart Citation

Is Genetic Vaccination against Allergy Possible?

Weiss

Scheiblhofer

Gabler

et al. 2006

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Genetic immunization has proven a powerful method to induce antiallergic immune responses. The underlying functional principle has been described to be based on the recruitment of allergen-specific Th1 cells, CD8+ cells and the establishment of a Th1 cytokine milieu, which prevent the development of a Th2-biased response in a protective setup and can balance an ongoing Th2-type response in a therapeutic situation. Genetic immunization with plasmid DNA offers innovative solutions to the major problems associated with protein immunization, such as crosslinking of pre-existing immunoglobulin E on mast cells/basophils or induction of de novo synthesis of immunoglobulin E by the protein immunization itself. It easily enables the routine production of hypoallergenic vaccines, which do not translate native allergens, thus avoiding potential anaphylactic side effects. DNA vaccines can also be applied as mixtures of single vaccines, making them interesting candidates for treatment based on component-resolved diagnosis, followed by an individualized therapy with the relevant allergens. In addition to the description of up-to-date allergen gene vaccine approaches, this review gives an overview of animal studies dealing with the following topics: danger signals as the inherent adjuvant properties, methods to optimize the vaccine immunogenicity, modulation of the immune response, nonparenteral applications and low-dose vaccination strategies.

show abstract

Section: Th1-biased Immunity – the Key To Dna-based Allergy Vaccinationsupporting

confidence: 76%

“…Both CD4+ and CD8+ T cells from DNA-immunized animals have been shown to contribute to the suppression of IgE antibody production by affecting the primary response and/or by propagating the Th1 memory response in a passive cell transfer system [11, 12]. …”

Section: Th1-biased Immunity – the Key To Dna-based Allergy Vaccinationmentioning

confidence: 99%

Is Genetic Vaccination against Allergy Possible?

Weiss

Scheiblhofer

Gabler

et al. 2006

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Moreover, the role of T cells underlying the suppression of IgE by DNA vaccination remains controversial. Whereas Hsu et al [17] found that only CD8+ T cells were the immunoregulatory T cells in DNA vaccination, the other reports found that both CD4+ and CD8+ T cells played some roles in DNA vaccination [20]. In the present study, we have also sought evidence that both CD4+ and CD8+ T cells play crucial roles in pCyn d 1-vaccinated mice.…”

Section: Introductionmentioning

confidence: 56%

“…Recent studies have shown that DNA vaccination is a simple approach to activate Th1 responses [17,18,19,20,21,22,23,24]. Unlike protein vaccines, DNA vaccines induce long-lasting intracellular expression of recombinant allergens and generate specific Th1 cells secreting predominantly interferon-γ (IFN-γ) [18,19,20,21,22,23]. IFN-γ can selectively inhibit activation of Th2 cells and IgE production by B cells [25].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Induction of Specific Th1 Responses and Suppression of IgE Antibody Formation by Vaccination with Plasmid DNA Encoding Cyn d 1

Huang

Chu

et al. 2012

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Background: DNA vaccines encoding allergens have been developed to prevent or to treat specific IgE responses. Objective: To evaluate the potential preventive and therapeutic effect of DNA vaccines encoding Cyn d 1 alone or combined with different adjuvants on specific allergies. Methods: Recombinant plasmid Cyn d 1 (pCyn d 1) was constructed by insertion of Cyn d 1 cDNA into the vector pcDNA3. BALB/c mice were injected with pCyn d 1 alone or plus adjuvants such as bupivacaine, bestatin, liposome, or CpG. Control mice were treated with pcDNA3 or PBS. They were boosted 3 weeks later and then sensitized twice with recombinant Cyn d 1 and alum. Their serum antibody responses and cytokine profiles of spleen cells were studied. Adoptive transfer of spleen cells of pCyn d 1-vaccinated mice was also performed. Results: Vaccination of mice with pCyn d 1 induced Th1 responses characterized by IgG2a responses and spleen cell secretion of interferon-γ. Vaccination with pCyn d 1 not only prevented the induction of specific IgE responses but also suppressed ongoing IgE responses. The mice receiving untreated, CD4+- or CD8+-depleted spleen cells from pCyn d 1-vaccinated mice all had suppression of IgE responses. Conclusion: This study confirms the prophylactic and therapeutic effects of DNA vaccines encoding Bermuda grass pollen allergen Cyn d 1 on specific IgE responses. Both CD4+ and CD8+ T cells are crucial for the immunomodulatory effect of pCyn d 1 on specific IgE responses.

show abstract

Prevention of allergen‐specific IgE production and suppression of an established Th2‐type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch‐pollen allergen

et al. 2003

View full text Add to dashboard Cite

In atopic patients, programming towards a preferential Th2 immunity leads to IgE antibody production and cellular Th2 immunity against otherwise harmless antigens. We report the development of prophylactic and therapeutic DNA vaccines for the major birch-pollen allergen, Bet v 1. We constructed three DNA vaccines, coding for the complete cDNA, coding for two hypoallergenic fragments or coding for a hypoallergenic Bet v 1 mutant. The protective effect was studied in mice pretreated by intradermal DNA injections, then sensitized with Bet v 1 protein. Mice pretreated with any of the three Bet v 1-specific DNA vaccines were protected against allergic sensitization to Bet v 1. Protection was characterized by a lack of Bet v 1-specific IgE production, a lack of basophil activation and an enhanced IFN-+ expression. DNA vaccines with wild-type Bet v 1 induced strong Bet v 1-specific antibody responses whereas DNA vaccines with hypoallergenic Bet v 1 derivatives induced no (fragments) or only transient (mutant) Bet v 1-specific antibody responses. A therapeutic approach with the fragment-DNA vaccine reduced IgE production and stimulated a sustained Th1 cytokine milieu. Our results demonstrate that DNA vaccines with hypoallergenic forms of the allergen specifically protect against sensitization and suppress established Th2-type responses. This concept may be applied for the development of safe and specific DNA vaccines for the prophylaxis and therapy of allergic diseases.

show abstract

Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11

Cited by 45 publications

References 29 publications

Is Genetic Vaccination against Allergy Possible?

Is Genetic Vaccination against Allergy Possible?

Induction of Specific Th1 Responses and Suppression of IgE Antibody Formation by Vaccination with Plasmid DNA Encoding Cyn d 1

Prevention of allergen‐specific IgE production and suppression of an established Th2‐type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch‐pollen allergen

Contact Info

Product

Resources

About